NCT02648672 - BPN14770 Single Ascending Dose Study in Healthy Male and Female Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

July 31, 2016

Conditions

Alzheimer's Disease

Interventions

DRUG

BPN14770

BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.

DRUG

Placebo

Trial Locations (1)

49007

Jasper Clinic, Kalamazoo